Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
Status:
Completed
Trial end date:
2018-08-30
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of photodynamic therapy using HPPH
in treating patients who are undergoing surgery for primary or recurrent head and neck
cancer. Photodynamic therapy (PDT) uses a drug, such as HPPH, that becomes active when it is
exposed to a certain kind of light. When the drug is active, tumor cells are killed. Giving
photodynamic therapy after surgery may kill any tumor cells that remain after surgery.